Appraisal in progress
Indication |
|||
| Status: In progress | |||
|
|||
Medicine details |
|||
| Medicine name | galsulfase (Naglazyme®) | ||
| Formulation | 1 mg/ml concentrate for solution for infusion | ||
| Reference number | 155 | ||
| Indication | Treatment of long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome) |
||
| Company | BioMarin Europe Ltd | ||
| BNF chapter | Nutrition & blood | ||
| Submission type | Directed | ||
| Status | In progress | ||
| AWMSG meeting date | 08/10/2024 | ||
| Date of issue | 20/09/2024 | ||
| Further information #155 |
|||